Patents by Inventor David C. Myles

David C. Myles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136553
    Abstract: The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.
    Type: Application
    Filed: December 23, 2024
    Publication date: May 1, 2025
    Inventors: Brian R. Hearn, David C. Myles, Reena Chawla, David Yeghikyan, Chandregowda Venkateshappa, Susanta Samajdar, Kalisankar Bera, Suraj Tatyasaheb Gore, Raymond A. Ng
  • Publication number: 20250059204
    Abstract: The present invention provides fused benzoisoxazolyl compounds represented by compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of the diseases or disorders mediated by KAT6A in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.
    Type: Application
    Filed: December 12, 2022
    Publication date: February 20, 2025
    Inventors: Chandregowda Venkateshappa, Kalisankar Bera, Chandrasekhar Abbineni, Susanta Samajdar, David C. Myles, Brian R. Hearn
  • Publication number: 20250049768
    Abstract: The present disclosure provides methods of treating a disease, disorder, or condition associated with ER+/HER2+ cancer using Compound 1, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 7, 2022
    Publication date: February 13, 2025
    Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher
  • Publication number: 20240226073
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: May 2, 2023
    Publication date: July 11, 2024
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20240131013
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: May 1, 2023
    Publication date: April 25, 2024
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Patent number: 11672785
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: June 13, 2023
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20230159619
    Abstract: A trigger-responsive immune-inactivating signaling polypeptide disclosed herein can include a modulating domain and an immune-inactivating moiety, such as a dominant negative signaling moiety or constitutively active signaling moiety. A modulating domain can be characterized by an ability to adopt a first state and a second state, and to transition between the first state and the second state when exposed to a trigger. When the modulating domain is in its first state, the immune-inactivating signaling moiety can be inhibited, and when the modulating domain is in its second state, the inhibition can be relieved. Further disclosed herein are compositions for the delivery of a trigger-responsive immune-inactivating signaling polypeptide. Also, methods for using a trigger-responsive immune-inactivating signaling polypeptide, including to regulate an activity of immune system cells, are disclosed.
    Type: Application
    Filed: February 23, 2018
    Publication date: May 25, 2023
    Inventors: Peter J. Kushner, Leslie Hodges Gallagher, Cyrus L. Harmon, David C. Myles, Richard Sun
  • Publication number: 20230129598
    Abstract: The present disclosure provides methods of treating estrogen receptor-associated diseases, disorders, and conditions.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 27, 2023
    Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher
  • Publication number: 20230109666
    Abstract: Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b]indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.
    Type: Application
    Filed: July 6, 2020
    Publication date: April 6, 2023
    Applicant: Olema Pharmaceuticals, Inc.
    Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
  • Publication number: 20220370421
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: December 6, 2021
    Publication date: November 24, 2022
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20220265616
    Abstract: Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.
    Type: Application
    Filed: July 6, 2020
    Publication date: August 25, 2022
    Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
  • Patent number: 11229630
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: January 25, 2022
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20210059991
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: April 17, 2020
    Publication date: March 4, 2021
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Patent number: 10624878
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: April 21, 2020
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20190247372
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 15, 2019
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Patent number: 10292971
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 21, 2019
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20180289679
    Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 11, 2018
    Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
  • Publication number: 20150197506
    Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
    Type: Application
    Filed: March 17, 2015
    Publication date: July 16, 2015
    Applicant: OLEMA PHARMACEUTICALS, INC.
    Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
  • Patent number: 9018244
    Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: April 28, 2015
    Assignee: Olema Pharmaceuticals, Inc.
    Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
  • Patent number: 8193241
    Abstract: 6- and 7-substituted coumarin and related 6- and 7-substituted 1H-quinolin-2-one compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the 7-substituted coumarin and related 7-substituted 1H-quinolin-2-one compounds mimic or exceed the high level of pharmacological activity of discodermolide. In other embodiments, their preparation involves more readily available materials, higher yield processes and/or simpler synthetic sequences. In yet other embodiments, the compounds of the invention represent structurally simpler, therapeutically active analogues of discodermolide than heretofore known and may be useful as microtubule stabilizers and, inter alia, for treating and/or preventing cancer and other diseases, disorders, and/or conditions mediated by the stabilization of microtubules.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: June 5, 2012
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Amos B. Smith, III, Simon J. Shaw, David C. Myles